Advertisement
The Athletes for Life Foundation has selected Signalife's award winningtechnology to perform heart monitoring and screening as part of the program'sactivities. The Signalife monitor is a 12 lead ambulatory ECG device capableof detecting subtle ECG changes that may be significant for early diagnosis ofpotential heart problems.
Advertisement
The Athletes for Life Foundation's co-founder, Willie Gault, commented: "Icannot begin to put into words how grateful I am to the NIH for inviting me tojoin their efforts in educating children. The foundation is bringingSignalife's heart monitoring and screening to the public, for free, as part ofits continued effort to shift the healthcare balance from costly reactiveheart disease treatments to early heart disease detection. A number of highprofile sports and media personalities have recently passed away from heartdisease. Perhaps use of this technology would have allowed life savingintervention. The foundation believes that providing annual heart screeningfor all people, before symptoms are apparent, can have an enormous impact inour efforts to save lives and lower the cost of healthcare throughout theworld. We are thankful to all those who have supported our efforts to 'savelives, one heart at a time'."
About Athletes for Life Foundation
The Athletes for Life Foundation, www.athletesforlife.com, is a non-profitfoundation whose membership includes a multitude of famous role models andathletes who have witnessed friends and colleagues die suddenly from cardiacdisease. The Athletes for Life Foundation is committed to promoting earlydiagnosis and treatment of cardiac disease in order to save lives. TheAthletes for Life Foundation is committed to bringing -- and does bring -- newtechnologies to healthcare. The Athletes for Life Foundation brings heartmonitoring to communities, so that health care comes to the masses and notvice versa, in its mission to "save lives, one heart at a time."
Signalife, Inc., www.signalife.com, is a life sciences company focused onthe monitoring, detection and prevention of disease through continuousbiomedical signal monitoring. Signalife uses its patented signal technologyto develop medical devices that provide clear trusted data acquisition toenable accurate timely diagnosis of heart disease. Signalife is publiclytraded on the American Stock Exchange under the symbol SGN. The website forthe company is http://www.signalife.com.
Caution Regarding Forward-Looking Statement
Statements in this release that are not strictly historical are"forward-looking" statements. Forward-looking statements involve known andunknown risks, which may cause Signalife's actual results in the future todiffer materially from expected results. Factors which could cause orcontribute to such differences include, but are not limited to, failure tocomplete the development and introduction of heart monitoring and otherbiomedical devices incorporating Signalife's technology, failure to obtainfederal or state regulatory approvals governing heart monitoring and otherbiomedical devices incorporating Signalife's technology, inability to obtainphysician, patient or insurance acceptance of for heart monitoring and otherbiomedical incorporating Signalife's technology, and the unavailability offinancing to complete management's plans and objectives, including thedevelopment
